Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia

Cancer

Volumn 115, Issue 23, 2009, Pages 5490-5498

  Thomas, Deborah A ^a   Kantarjian, Hagop M ^a   Stock, Wendy ^b   Heffner, Leonard T ^c   Faderl, Stefan ^a   Garcia Manero, Guillermo ^a   Ferrajoli, Alessandra ^a   Wierda, William ^a   Pierce, Sherry ^a   Lu, Biao ^d   Deitcher, Steven R ^d   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Chicago   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Hana Biosciences   (United States)

Author keywords

Acute lymphoblastic leukemia; Liposome; Salvage therapy; Vincristine

Indexed keywords

AMINOTRANSFERASE; DEXAMETHASONE; FLUCONAZOLE; ITRACONAZOLE; MARQIBO; UNCLASSIFIED DRUG; VINCRISTINE SULFATE LIPOSOME INJECTION; VORICONAZOLE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLURRED VISION; BONE PAIN; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SUBSTITUTION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOTENSION; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; MENTAL HEALTH; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; URINE RETENTION; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SALVAGE THERAPY; VINCRISTINE;

EID: 72249112336     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24632     Document Type: Article

References (23)

1. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646-1654.
2. Owellen RJ, Owens AH Jr, Donigian DW.The binding of vincristine, vinblastine and colchicine to tubulin. Biochem Biophys Res Commun. 1972;47:685-691.
3. Owellen RJ, Hartke CA, Dickerson RM, Hains FO.Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 1976;36:1499-1502.
4. Owellen RJ, Root MA, Hains FO.Pharmacokinetics of vindesine and vincristine in humans. Cancer Res. 1977;37(8 pt 1): 2603-2607.
5. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS.Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol. 1999;44:203-209. (Pubitemid 29350175)
6. Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr. 1994;125:642-649. (Pubitemid 24318444)
7. Weiden PL, Wright SE.Vincristine neurotoxicity. N Engl J Med. 1972;286:1369-1370.
8. Legha SS.Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol. 1986;1:421-427.
9. Balis FM, Holcenberg JS, Poplack DG. General principles of chemotherapy. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 3rd ed. Philadelphia, Pa: Lippincott-Raven;1997:215-272.
10. Boman NL, Mayer LD, Cullis PR.Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta. 1993;1152:253-258.
11. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD.Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995;72:896-904.
12. Krishna R, Webb MS, St Onge G, Mayer LD.Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001;298:1206-1212. (Pubitemid 32761941)
13. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR.Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 1990;50: 575-579. (Pubitemid 20054181)
14. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB.Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994;54:2830-2833. (Pubitemid 24187755)
15. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB.Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer. 1995;71:482-488.
16. Leonetti C, Scarsella M, Semple SC, et al. In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. Int J Cancer. 2004;110:767-774.
17. Gelmon KA, Tolcher A, Diab AR, et al. Phase I study of liposomal vincristine. J Clin Oncol. 1999;17:697-705.
18. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000; 11:69-72. (Pubitemid 30084582)
19. Thomas DA, Sarris AH, Cortes J, et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer. 2006;106:120-127. (Pubitemid 43032556)
20. Thomas DA, Kantarjian HM, Stock W, et al. Safety and efficacy of Marqibo (vincristine sulfate liposomes injection, Optisome) for the treatment of adults with relapsed or refractory acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2007;110:263a. Abstract 858.
21. Cox DR.Regression models and life tables. J R Stat Soc B. 1972;34:187-220.
22. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999;86:1216-1230. (Pubitemid 29447005)
23. O'Brien S, Thomas DA, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia with second salvage therapy. Cancer. 2008;113:3186-3191.